Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive troriluzole versus placebo for obsessive-compulsive disorder
NL-OMON52232Phase 3Not yet recruiting
- Sponsor
- Accelsiors
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Troriluzole adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NL-OMON52232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52232.